Posted by Michael Wonder on 30 Sep 2022
European Medicines Agency accepts Astellas’ marketing authorisation application for fezolinetant
30 September 2022 - If authorized by the European Commission, fezolinetant would be a nonhormonal treatment for moderate to severe vasomotor symptoms associated with menopause.
Astellas Pharma today announced the EMA has accepted for regulatory review the company’s marketing authorisation application for fezolinetant, an investigational oral, non-hormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms associated with menopause.
